Mabion (STU:272) Short Interest


STU:272 Mabion SA STU:272
29 GF Score
Price €1.69
GF Value €0.47
! 5 Warning Signs
View Full Analysis

What is Mabion Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

STU:272 vs VRTX, REGN, ALNY: Short Interest Comparison

For the Biotechnology subindustry, Mabion's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mabion Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mabion's Short Interest distribution charts can be found below:

* The bar in red indicates where Mabion's Short Interest falls into.


STU:272
29GF Score
Mabion SA STU:272
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Mabion (STU:272) Overvalued in 2026?

Based on GuruFocus' analysis, Mabion stock appears to be overvalued. The current stock price of €1.69 is trading 259.1% above its estimated GF Value™ of €0.47.

Key valuation signals for STU:272:

  • Short Interest:
  • GF Value™: €0.47 vs. price of €1.69 (259.1% above fair value)
  • GF Score™: 29/100 with 5 warning signs

No single metric tells the full story. See the STU:272 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mabion Business Description

Other Exchanges MAB:Poland272:Germany
Address ul. Gen. Mariana Langiewicza 60, Konstantynow Lodzki, POL, 95-050
Mabion SA is a Polish biotechnology company focused on developing and launching modern biotechnology drugs based on monoclonal antibody technology. The drugs developed by the company are targeted treatments, characterized by the drug's ability to recognize the factor causing cancer and interact with this factor only. The company is working on the development of its main priority drug, referred to as the MabionCD20 drug. The therapeutic uses of MabionCD20 are for Non-Hodgkin's lymphoma, Leukemia, and Rheumatoid Arthritis.
29GF Score

Get the complete analysis for STU:272

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.69
Price
€0.47
GF Value